Vericel, developer of MACI® autologous cultured chondrocytes for cartilage repair, priced its underwritten public offering of 5MM shares of common stock at $13/share.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more